MD3288940T2 - Azabenzimidazoli și utilizarea lor ca modulatori ai receptorilor AMPA - Google Patents

Azabenzimidazoli și utilizarea lor ca modulatori ai receptorilor AMPA

Info

Publication number
MD3288940T2
MD3288940T2 MDE20180234T MDE20180234T MD3288940T2 MD 3288940 T2 MD3288940 T2 MD 3288940T2 MD E20180234 T MDE20180234 T MD E20180234T MD E20180234 T MDE20180234 T MD E20180234T MD 3288940 T2 MD3288940 T2 MD 3288940T2
Authority
MD
Moldova
Prior art keywords
azabenzimidazoles
receptor modulators
ampa receptor
compounds
formula
Prior art date
Application number
MDE20180234T
Other languages
English (en)
Inventor
Cynthia G B Berry
Gang Chen
Fabrice Loic Jourdan
Terry Patrick Lebold
David Wei Lin
Pinon Miguel Angel Pena
Suchitra Ravula
Bradley M Savall
Devin M Swanson
Dongpei Wu
Wei Zhang
Michael K Ameriks
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MD3288940T2 publication Critical patent/MD3288940T2/ro

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/04Systems containing only non-condensed rings with a four-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Sunt furnizaţi aici compuşi cu Formula (I), şi săruri acceptabile farmaceutic, N-oxizi, sau solvaţi ai acestora,Sunt de asemenea furnizate aici compoziţii farmaceutice care cuprind compuşii cu Formula (I) şi metode de utilizare a compuşilor cu Formula (I).
MDE20180234T 2015-04-29 2016-04-28 Azabenzimidazoli și utilizarea lor ca modulatori ai receptorilor AMPA MD3288940T2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562154313P 2015-04-29 2015-04-29
PCT/US2016/029801 WO2016176460A1 (en) 2015-04-29 2016-04-28 Azabenzimidazoles and their use as ampa receptor modulators

Publications (1)

Publication Number Publication Date
MD3288940T2 true MD3288940T2 (ro) 2021-08-31

Family

ID=56008859

Family Applications (1)

Application Number Title Priority Date Filing Date
MDE20180234T MD3288940T2 (ro) 2015-04-29 2016-04-28 Azabenzimidazoli și utilizarea lor ca modulatori ai receptorilor AMPA

Country Status (39)

Country Link
US (4) US11312712B2 (ro)
EP (3) EP3901153A1 (ro)
JP (2) JP6800886B2 (ro)
KR (2) KR20240017991A (ro)
CN (1) CN107835814B (ro)
AR (1) AR104447A1 (ro)
AU (2) AU2016255434C1 (ro)
BR (2) BR112017023147B1 (ro)
CA (1) CA2983826A1 (ro)
CO (1) CO2017011017A2 (ro)
CR (1) CR20170484A (ro)
CY (1) CY1124059T1 (ro)
DK (1) DK3288940T5 (ro)
EA (1) EA033281B1 (ro)
EC (1) ECSP17074645A (ro)
ES (1) ES2865330T3 (ro)
GT (1) GT201700231A (ro)
HK (1) HK1252249A1 (ro)
HR (1) HRP20210403T1 (ro)
HU (1) HUE053943T2 (ro)
IL (1) IL254848B (ro)
JO (1) JO3654B1 (ro)
LT (1) LT3288940T (ro)
MA (1) MA41988B1 (ro)
MD (1) MD3288940T2 (ro)
MX (1) MX2017013886A (ro)
MY (1) MY194104A (ro)
NI (1) NI201700129A (ro)
PH (1) PH12017501816A1 (ro)
PL (1) PL3288940T3 (ro)
PT (1) PT3288940T (ro)
RS (1) RS61688B1 (ro)
SG (1) SG11201708190UA (ro)
SI (1) SI3288940T1 (ro)
TW (1) TWI706952B (ro)
UA (1) UA120304C2 (ro)
UY (1) UY36654A (ro)
WO (1) WO2016176460A1 (ro)
ZA (1) ZA201708065B (ro)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016176457A1 (en) * 2015-04-29 2016-11-03 Janssen Pharmaceutica Nv Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
CN107383004B (zh) * 2017-07-05 2020-04-17 浙江大学 2-氨基咪唑并吡啶类衍生物及制备和应用
CN111315735B (zh) * 2017-09-04 2024-03-08 C4医药公司 二氢苯并咪唑酮
ES2971497T3 (es) 2017-10-06 2024-06-05 Takeda Pharmaceuticals Co Compuestos heterocíclicos
CN113490668A (zh) 2018-10-05 2021-10-08 安娜普尔纳生物股份有限公司 用于治疗与apj受体活性有关的疾病的化合物和组合物
JP2022510501A (ja) * 2018-10-30 2022-01-26 リペア セラピューティクス インコーポレイテッド 化合物、医薬組成物、ならびに化合物の調製方法及びatrキナーゼ阻害剤としてのその使用方法
JP2022541825A (ja) * 2019-07-22 2022-09-27 リペア セラピューティクス インコーポレイテッド Atrキナーゼ阻害剤としての置換2-モルホリノピリジン誘導体
WO2022133046A2 (en) * 2020-12-16 2022-06-23 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
CN114591338B (zh) * 2022-03-31 2023-05-09 苏州欧康维视生物科技有限公司 一种Syk和VEGFR2双靶点抑制剂的制备方法及其用途
CN115304599A (zh) * 2022-09-20 2022-11-08 浙大宁波理工学院 一种3-溴-6-异丙基-1氢-哌咯[2,3-b]并吡啶及其制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55167282A (en) 1979-06-12 1980-12-26 Fujisawa Pharmaceut Co Ltd Piperazine derivative or its salt and its preparation
CN1051313A (zh) 1990-11-07 1991-05-15 鞍山市振东工业尼龙厂 尼龙球磨罐及其热装工艺
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
TW251284B (ro) * 1992-11-02 1995-07-11 Pfizer
CA2183084A1 (en) * 1994-02-10 1995-08-17 John Eugene Macor 5-heteroarylindole derivatives
US5565483A (en) 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
UA54403C2 (uk) 1996-10-01 2003-03-17 Н'Юросерч А/С Похідні індол-2,3-діон-3-оксиму, фармацевтична композиція, спосіб лікування розладу чи захворювання ссавців, у тому числі людини та спосіб одержання похідних індол-2,3-діон-3-оксиму
DE19812331A1 (de) 1998-03-20 1999-09-23 Merck Patent Gmbh Piperidinderivate
JP2002519373A (ja) * 1998-07-02 2002-07-02 エーザイ株式会社 製薬組成物及びそれらの使用
WO2000038519A1 (en) 1998-12-31 2000-07-06 Sugen, Inc. 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy
GB0018473D0 (en) 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
WO2002014294A2 (en) 2000-08-11 2002-02-21 Eli Lilly And Company Heterocyclic sulfonamide derivatives and their use for potentiating glutamate receptor function
US6548576B1 (en) 2001-11-07 2003-04-15 Bourns, Inc. Epoxy formulation adapted to be used in conjunction with no-lead solder in electronic components
GT200500185A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
ZA200701666B (en) * 2004-09-03 2008-07-30 Laboratroires Serono Sa Pyridine méthylène azolidinones and use thereof phospho-inositide inhibitors
EA016286B1 (ru) 2005-09-30 2012-03-30 Глэксо Груп Лимитед Соединения, которые обладают активностью по отношению к рецепторам м, и их применения в медицине
WO2007135529A2 (en) * 2006-05-23 2007-11-29 Pfizer Products Inc. Azabenzimidazolyl compounds as mglur2 potentiators
DE602007013450D1 (de) 2006-11-03 2011-05-05 Glaxo Group Ltd Verbindungen, die den ampa-rezeptor verstärken, und deren anwendung in der medizin
WO2008113795A1 (en) 2007-03-20 2008-09-25 Glaxo Group Limited Compounds which potentiate ampa receptor and uses thereof in medicine
GB0711089D0 (en) 2007-06-08 2007-07-18 Glaxo Group Ltd Compounds
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
WO2009067607A2 (en) 2007-11-20 2009-05-28 Memory Pharmaceuticals Corporation Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders
JP2011506335A (ja) * 2007-12-06 2011-03-03 シェーリング コーポレイション γ−セクレターゼ調節剤
TW201012803A (en) * 2008-06-06 2010-04-01 Organon Nv Heterocyclic derivatives
WO2010005528A2 (en) * 2008-06-30 2010-01-14 Ironwood Pharmaceuticals Incorporated Pyrrolopyridine carboxylic acid derivatives
GB0822425D0 (en) 2008-12-09 2009-01-14 Glaxo Group Ltd Compounds
GB0822981D0 (en) 2008-12-17 2009-01-21 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
WO2011056985A2 (en) 2009-11-04 2011-05-12 Gilead Sciences, Inc. Substituted heterocyclic compounds
US8765784B2 (en) * 2010-06-09 2014-07-01 Merck Sharp & Dohme Corp. Positive allosteric modulators of MGLUR2
PE20131116A1 (es) 2010-08-10 2013-10-24 Takeda Pharmaceutical Compuestos heterociclicos potenciadores de ampa
WO2012021382A1 (en) 2010-08-12 2012-02-16 Merck Sharp & Dohme Corp. Positive allosteric modulators of mglur2
EP2773641B1 (en) 2011-10-31 2017-09-27 Xenon Pharmaceuticals Inc. Biaryl ether sulfonamides and their use as therapeutic agents
WO2013130501A1 (en) * 2012-03-01 2013-09-06 The Board Of Regents Of The University Of Texas System Bivalent ampa receptor positive allosteric modulators
GB201205669D0 (en) * 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
JO3225B1 (ar) 2012-11-27 2018-03-08 Lilly Co Eli 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8
MX2015010714A (es) * 2013-02-19 2016-06-14 Pfizer Compuestos de azabencimidazol.

Also Published As

Publication number Publication date
MX2017013886A (es) 2018-03-12
JP2021042230A (ja) 2021-03-18
US20230110576A1 (en) 2023-04-13
AR104447A1 (es) 2017-07-19
US20180118740A1 (en) 2018-05-03
UA120304C2 (uk) 2019-11-11
UY36654A (es) 2016-10-31
ECSP17074645A (es) 2018-02-28
CY1124059T1 (el) 2022-05-27
GT201700231A (es) 2018-12-20
CR20170484A (es) 2018-02-26
JP7026194B2 (ja) 2022-02-25
LT3288940T (lt) 2021-05-10
NI201700129A (es) 2019-05-10
PH12017501816A1 (en) 2018-04-23
US20230114165A1 (en) 2023-04-13
EP3288940B1 (en) 2021-02-24
IL254848B (en) 2021-01-31
HRP20210403T1 (hr) 2021-10-29
NZ736057A (en) 2023-08-25
KR20240017991A (ko) 2024-02-08
DK3288940T5 (da) 2021-09-20
TWI706952B (zh) 2020-10-11
EP3288940B9 (en) 2021-07-21
SG11201708190UA (en) 2017-11-29
ES2865330T3 (es) 2021-10-15
EP4144736A1 (en) 2023-03-08
EA033281B1 (ru) 2019-09-30
HK1252249A1 (zh) 2019-05-24
AU2016255434A1 (en) 2017-10-26
HUE053943T2 (hu) 2021-08-30
CN107835814A (zh) 2018-03-23
CN107835814B (zh) 2021-07-23
DK3288940T3 (da) 2021-05-25
KR20170140382A (ko) 2017-12-20
BR122023023802A2 (pt) 2023-12-26
JP6800886B2 (ja) 2020-12-16
MA41988A (fr) 2018-07-03
CO2017011017A2 (es) 2018-03-20
SI3288940T1 (sl) 2021-07-30
CA2983826A1 (en) 2016-11-03
ZA201708065B (en) 2019-09-25
TW201708217A (zh) 2017-03-01
JP2018518462A (ja) 2018-07-12
EA201792374A1 (ru) 2018-05-31
US20210284641A1 (en) 2021-09-16
AU2016255434B2 (en) 2020-05-14
AU2016255434C1 (en) 2021-09-23
BR112017023147B1 (pt) 2024-04-30
MA41988B1 (fr) 2021-03-31
BR112017023147A2 (pt) 2018-07-10
MY194104A (en) 2022-11-11
WO2016176460A1 (en) 2016-11-03
US11312712B2 (en) 2022-04-26
AU2020210231A1 (en) 2020-08-20
PT3288940T (pt) 2021-04-30
IL254848A0 (en) 2017-12-31
PL3288940T3 (pl) 2021-07-12
EP3288940A1 (en) 2018-03-07
JO3654B1 (ar) 2020-08-27
RS61688B1 (sr) 2021-05-31
AU2020210231B2 (en) 2021-07-22
EP3901153A1 (en) 2021-10-27

Similar Documents

Publication Publication Date Title
MD3288940T2 (ro) Azabenzimidazoli și utilizarea lor ca modulatori ai receptorilor AMPA
MD3313817T2 (ro) Derivați biciclici, un procedeu pentru prepararea lor și compozițiile farmaceutice care îi conțin
MX2016016593A (es) Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos.
TR201904658T4 (tr) Bisiklik füzyonla birleştirilmiş heteroaril veya aril bileşikleri ve bunların ırak4 inhibitörleri olarak kullanımları.
MD3313850T2 (ro) Noi derivaţi de aminoacizi, procedeu pentru prepararea acestora şi compoziţii farmaceutice care îi conţin
MX2017013877A (es) Compuestos de benzimidazolona y benzotiazolona y su uso como moduladores del receptor ampa.
MD3319612T2 (ro) Oxisteroli și metode de utilizare a acestora
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
EA201201263A1 (ru) Фармацевтическая композиция, содержащая этексилат дабигатрана
PH12019501639A1 (en) Jaki selective inhibitors
PH12016501624A1 (en) 1,2-substituted cyclopentanes as orexin receptor antagonists
MA39956A (fr) Analogues du benzomorphane et leur utilisation
NZ729252A (en) Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof
EA201790627A1 (ru) СТИМУЛЯТОРЫ рГЦ
EA201201202A1 (ru) Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана
MD3303331T2 (ro) Modulatori alosterici pozitivi ai receptorilor muscarinici M1
MX2018015872A (es) Derivados de benzodioxano y su uso farmaceutico.
MD3265459T2 (ro) Compuși amidici în calitate de agoniști ai receptorilor 5-HT4
NZ731607A (en) Dihydropyrimidin-2- one compounds and medical use thereof
ZA201903291B (en) Fused bicylic pyridine compounds and their use as ampa receptor modulators
CR20160527A (es) Derivados de carboxamida
UY36117A (es) Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas.
PH12016501625A1 (en) Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists
EA201991045A1 (ru) Конденсированные азагетероциклические соединения и их применение в качестве модуляторов ampa-рецептора
MX2017013885A (es) Compuestos de indolona y su uso como moduladores del receptor ampa.